Ipsen adds another program into its pre-clinical R&D Oncology pipeline through an exclusive worldwide collaboration with Accent Therapeutics, targeting the RNA modifying protein, METTL3 .
/PRNewswire/ Accent Therapeutics, a biopharmaceutical company developing breakthrough, oncology-focused small molecule therapies that target RNA-modifying.
Accent Therapeutics Presents Data Supporting DHX9 Inhibition as a Novel Therapeutic Modality at American Association for Cancer Research (AACR) Annual Meeting 2023 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Ipsen obtains an exclusive license to develop, manufacture and commercialize a pre-clinical stage METTL3-inhibitor program Building on recent announcements, this collaboration with Accent